Med24
clinical-research 10. 11. 2026 • 2 min read • ClinicalTrials.gov (M.D. Anderson Cancer Center)

A Phase I/II Study of Liposomal Cytarabine and Daunorubicin (CPX-351) in Combination With Quizartinib in Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS)

This phase I/II trial studies the side effects and best dose of CPX-351 in combination with quizartinib for the treatment of acute myeloid leukemia and high risk myelodysplastic syndrome. CPX-351, composed of chemotherapy drugs daunorubicin and cytarabine, works in different ways to stop the growth of cancer cells,...

Kuva MASLD:stä (metabolinen oireyhtymä-lihasrasvushierova) tyypillisessä diabeteksessa, esimerkinä Kuwaitissa.

This phase I/II clinical trial investigates the safety and optimal dosage of Liposomal Cytarabine and Daunorubicin (CPX-351) combined with Quizartinib for individuals with Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (HR-MDS). The study aims to determine the maximum tolerable dose of CPX-351, a formulation containing chemotherapy drugs daunorubicin and cytarabine, which function by killing cancer cells, preventing cell division, and inhibiting cell spread. Quizartinib, administered orally, may inhibit tumor cell growth by blocking specific enzymes involved in cell proliferation. The trial enrolls 52 participants with conditions including newly diagnosed or relapsed refractory AML and HR-MDS. Patients receive CPX-351 intravenously over 90 minutes on days 1, 3, and 5, alongside quizartinib orally on days 6-19. Treatment cycles consist of an induction phase, a consolidation phase, and a maintenance phase, repeating every 28 days for up to two cycles unless disease progression or unacceptable toxicity occurs. The primary objectives include determining the MTD of CPX-351 and quizartinib, and measuring the overall response rate (ORR) encompassing complete remission (CR), complete remission with incomplete platelet recovery (CRp), complete remission with incomplete count recovery (CRi), and partial remission (PR) within three months. Secondary objectives involve assessing overall survival (OS), event-free survival (EFS), and duration of response (DOR). Exploratory objectives include evaluating the ORR, EFS, and OS in patients with FLT3 mutated/NPM1 wild-type versus other FLT3 mutated/NPM1 mutated patient subgroups. The study also investigates quantitative changes in FLT3-ITD allelic burden and longitudinal evaluation of mutations over time. Furthermore, the trial assesses the impact of the treatment combination on patients transitioning to hematopoietic stem cell transplant (HSCT) and includes the collection of surplus blood or tissue for potential future research into factors influencing AML development and treatment response. Patient follow-up extends to 30 days, then every 3-6 months for up to 5 years.

Sponsored content

Original Scientific Source
ClinicalTrials.gov (M.D. Anderson Cancer Center)
View Original Source
Medical Disclaimer All calculations, recommendations, and interpretations provided by this tool are for informational and educational purposes only. They do not substitute professional medical advice, diagnosis, or treatment. Always consult your physician regarding any health concerns.

Recommended Medical News

All news →
Evaluation of the Espansione Equinox System Safety & Effectiveness for the Treatment of Meibomian Gland Dysfunction: A Prospective, Multicenter, Randomized Controlled Investigation
clinical-research

Evaluation of the Espansione Equinox System Safety & Effectiveness for the Treatment of Meibomian Gland Dysfunction: A Prospective, Multicenter, Randomized Controlled Investigation

The purpose of this study is to demonstrate the non-inferiority of the Equinox System with respect to iLux 2020. Approximately 120 participants are expected to take part in the research trial at a minimum of three (3) and up to five (5) sites across the United States. The expected duration of the study will be six (6)...

16. 11. 2026 Read article →
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant C
clinical-research

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant C

This randomized phase III trial studies how well pembrolizumab works in treating patients with triple-negative breast cancer. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.

16. 11. 2026 Read article →
Comparison of Clinical Outcomes Associated With Different Transcranial Magnetic Stimulation Protocols Combined With Botulinum Toxin-A Injection in Post-Stroke Upper Limb Spasticity
clinical-research

Comparison of Clinical Outcomes Associated With Different Transcranial Magnetic Stimulation Protocols Combined With Botulinum Toxin-A Injection in Post-Stroke Upper Limb Spasticity

Post-stroke upper limb spasticity is an important condition that negatively affects motor recovery, upper limb functions, and activities of daily living. Multimodal treatment approaches are recommended in the management of spasticity. In recent years, the effects of transcranial magnetic stimulation (TMS) on upper...

10. 11. 2026 Read article →
Advertisement